Tyra Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Tyra Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($119.95M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($86.48M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($69.13M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($55.33M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($26.29M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($9.34M) | Mar 3, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($132.76M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($104.18M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($79.95M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($58.93M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($26.29M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($9.30M) | Mar 3, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.93M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $80.08M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $62.52M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $43.01M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $20.64M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $7.20M | Mar 3, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($95.14M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($69.77M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($50.14M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($50.29M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($23.75M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($7.76M) | Mar 3, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $664.0K | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $770.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $559.0K | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $661.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $312.0K | Mar 3, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $282.61M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $363.56M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $225.86M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $266.18M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $306.70M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $16.01M | Mar 3, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.43M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $20.41M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $21.60M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.35M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $4.96M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $2.00M | Mar 3, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $259.18M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $343.15M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $204.26M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $257.83M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $301.74M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | ($13.64M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | ($4.74M) | Mar 3, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($371.26M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($251.31M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($164.83M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($95.70M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($40.37M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($14.08M) | Mar 3, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.39M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $91.97M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $58.01M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $251.21M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $302.18M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $15.22M | Mar 3, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 22, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 53.71M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 50.75M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 43.02M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 42.35M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 41.44M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 1.83M | Mar 3, 2022 |